William D Figg

Sep 18, 2024 | nature.com | Malin Hultcrantz |Hani Hassoun |Neha Korde |Kylee H. Maclachlan |Sham Mailankody |Urvi A. Shah | +9 more

Letter to the EditorLenalidomide is an immunomodulatory drug that is recommended and widely used as part of induction therapy and maintenance for multiple myeloma (MM) [1]. Lenalidomide maintenance is associated with significantly improved progression-free and overall survival, as shown in several clinical trials and meta-analyses [2,3,4,5,6,7]. Most patients tolerate lenalidomide well; however, fatigue and diarrhea are common side effects in the maintenance phase [3, 7, 8].

Dec 4, 2023 | nature.com | Shahabbedin Sotudian |Xintao Qiu |Renee Maria Saliby |Rong Li |Cindy H Chau |James A. DeCaprio | +14 more

Correction to: Nature Medicine https://doi.org/10.1038/s41591-023-02605-z, published online 21 October 2023. This article was originally published under a standard Springer Nature license (© The Author(s), under exclusive licence to Springer Nature America, Inc.); it is now available as an open-access paper under a Creative Commons Attribution 4.0 International license, © The Author(s). The error has been corrected in the HTML and PDF versions of the article.

Oct 21, 2023 | nature.com | Xintao Qiu |Renee Maria Saliby |Rong Li |Cindy H Chau |James A. DeCaprio |William D Figg | +14 more

AbstractAlthough circulating tumor DNA (ctDNA) assays are increasingly used to inform clinical decisions in cancer care, they have limited ability to identify the transcriptional programs that govern cancer phenotypes and their dynamic changes during the course of disease. To address these limitations, we developed a method for comprehensive epigenomic profiling of cancer from 1 ml of patient plasma.